On September 10, 2018, a tiny Cambridge biotech firm won a patent on a new kind of treatment that can "Cut & Paste" any disease from your body. To learn more read below.
 | You're receiving this email because you are subscribed to Trading Tips,
if you no longer wish to receive these emails you can Manage Subscriptions. |  |  | |
| EDITOR'S NOTE: On September 10, 2018, a tiny Cambridge biotech firm won a patent on a new kind of treatment that can "Cut & Paste" any disease from your body. To learn more read below. | | | Dear Investor,
Cytarbine.
That's the name of the most popular drug doctors prescribed last year to fight leukemia.
Problem is, Cytarbine is a "chemical drug" that was patented almost 60 years ago. Chemical drugs are like nuclear weapons. Drop them inside your body and everything gets destroyed. It's why people say, "the chemo will get you before the cancer does."
It gets even worse...
75% of all cancer drugs sold by Big Pharma are old chemical drugs like Cytarbine.
Well guess what?
On September 10, 2018, a tiny Cambridge biotech firm won a patent on a new kind of treatment that can "Cut & Paste" any disease from your body.
It's like this tiny biotech invented the iPhone while Big Pharma is still selling flip phones.
And our research proves that anyone who gets in today could turn every $1,000 into $1.54 million (or more)!
The Big Pharma companies that have the most to lose from this new treatment are Bristol Meyers, Pfizer, Sanofi, Novartis and Teva.
Sanofi has their own new drug on the market. Pfizer last month bought Array Biopharma, which we recommended. That leaves Novartis, Teva and Bristol Meyers.
We think Bristol Meyers is the most likely buyer because their new leukemia drug recently flunked out of FDA trials.
A deal could happen any day.
A takeover of the company could hand investors gains of up to $31,250 in the next 90 days...
But we would be ok if there wasn't a deal.
That's because Investor's Business Daily estimates this is a $75 billion market.
Yet right now, its stock price is just a tiny fraction of that size.
CLICK HERE to see how you can profit from this rare opportunity>>>
Sincerely,
Josh Kaplan
Editor-in-Chief,
Behind the Markets
| | |
| | | |
| From time to time your free Trading Tips newsletter subscription is supplemented by paid sponsorships, like the one above. Please read all disclaimers. Rest assured that your information was not shared with this sponsor. Please note that Trading Tips has not independently reviewed the validity of the claims or statements contained within this sponsorship, and we are not responsible for any errors or omissions.
Never invest in a security or idea featured on our site or in our emails unless you can afford to lose your entire investment. We are not registered investment advisors or brokers/dealers and we do not purport to be. We make no representations, warranties or guarantees as to the accuracy or completeness of the content featured on our site or in our emails. Furthermore, the article authors and contributors featured on this site may own securities mentioned in their articles and not disclose this information. Trading Tips does not endorse any investing or trading products or newsletters advertised in this email or on our web site. Please be sure to read our
Go here to get more information from http://www.TradingTips.com | | | | | |
No comments:
Post a Comment